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ABSTRACT
Conclusion This is the first controlled study of balloon sinuplasty’s long-term efficacy with the
follow-up time over 5 years. The results are in accordance with a previous 2-year-follow-up study.
Both techniques retained the efficacy and patient satisfaction on average 6 years after the surgery.
Background Endoscopic sinus surgery (ESS) and balloon sinuplasty are considered as a treatment
for chronic rhinosinusitis (CRS) after a failure of conservative therapy. High cost and lack of long-
term follow-up studies restrain the use of balloon sinuplasty.
Objective The aim of this study was to compare long-term efficacy and satisfaction in CRS patients
who had undergone maxillary sinus operation with either balloon sinuplasty or ESS technique.
Previous or additional sinonasal operations were exclusion criteria.
Materials and methods Study patients were recruited from 208 CRS-patients who underwent
either ESS or balloon sinuplasty. Patients with nasal polyposis (gradus  2), previous sinonasal
surgery, unilateral disease, or immune deficiency were excluded. Altogether 45 patients in the ESS
group and 40 patients in the balloon group were included. Of these, 30 and 28, respectively,
answered to a phone interview held on average 6 years after primary surgery. Symptom reduction
and long-term satisfaction were evaluated by using symptom scores of 19 parameters altogether.
Results Both groups experienced improvement in symptoms and were equally satisfied with the
operation. The number of patient-reported acute exacerbations was higher among the balloon
dilated patients. Also, the reduction of thick nasal discharge was less evident in the balloon
sinuplasty group. Four patients in the balloon sinuplasty group underwent revision surgery. There
were no revisions in the ESS group.
ARTICLE HISTORY
Received 5 October 2015
Revised 25 November 2015
Accepted 30 November 2015
Published online 21 January
2016
KEYWORDS
Balloon sinuplasty; chronic
rhinosinusitis; endoscopic
sinus surgery; long-term
efficacy; satisfaction
Introduction
Chronic rhinosinusitis (CRS) is a common, diverse, and
multifactorial disease of the nose and paranasal sinuses, with
a prevalence of 10% [1]. It has a severe impact on quality-
of-life and national economy [2,3]. Diagnosis is based on
characteristic symptoms lasting more than 12 weeks,
computed tomography (CT) scan and/or endoscopic changes
[4]. Conservative treatment of CRS with intranasal saline
irrigations and corticosteroids is always prior to surgery.
Internationally, endoscopic sinus surgery (ESS) is con-
sidered as a treatment modality in CRS after the failure of
medical treatment, even though the Cochrane Collaboration
has stated that ESS offers no additional benefit to that
obtained by medical treatment in relieving the symptoms of
CRS. Nevertheless, patients with a prolonged and chronic
disease with a severe impact on quality-of-life might benefit
more from surgery than continued medical therapy [5].
Controlled studies have shown quality-of-life (QoL)
improvement after ESS and balloon sinuplasty [2,6,7].
Balloon sinuplasty has been under an intensive evaluation
during the last decade. The principle of balloon sinuplasty is
to dilate the ostium without removing any bone or tissue
[8]. The guide wire is advanced into the maxillary sinus and
the right place is verified with transillumination or fluoros-
copy technique [8]. The balloon catheter is steered into the
ostium via the guide wire and inflated up to 8–12 bars for a
few seconds, resulting in a wider passage to the blocked
sinus and facilitating the drainage of the mucus. The
disadvantages of the procedure are the lack of knowledge of
its long-term effect, the high costs of the disposable
instruments, and its technical limitations in ethmoidal area
or in removal of atypical mucosa [9]. Several uncontrolled
and controlled studies have suggested balloon sinuplasty to
be a safe and effective method [6,7,10–13]. However, the
limitations of these studies are the heterogeneity of patients
and procedures as well as short follow-up time, which makes
the conclusions difficult to draw. In our 2-year follow-up
study we demonstrated that patient satisfaction and symp-
tom reduction were equal in both groups. However, in
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number of acute exacerbations ESS seems to be superior to
balloon sinuplasty [14].
Methods
Patients
The study was approved by the ethical committee of the
Pirkanmaa Hospital District. Overall, 208 patients suffering
from chronic rhinosinusitis, who were evaluated to benefit
from maxillary sinus operation, were enrolled in this study.
Altogether 103 patients underwent bilateral balloon sinuplasty
and 105 patients bilateral ESS of the maxillary sinuses. Balloon
procedures were carried out between 2008–2009 at two
private clinics (Terveystalo Healthcare OYJ of Finland and
Koskiklinikka Tampereen la¨a¨ka¨rikeskus Oy) in Tampere,
Finland. ESS, partial uncinectomy, and middle meatal
antrostomy were carried out at Pa¨ija¨t-Ha¨me Central
Hospital, in Lahti, Finland, during 2008–2010. Only patients
having a simple bilateral maxillary sinus operation were
included.
Patients’ medical records and pre-operative computed
tomography or magnetic resonance (CT/MRI) scans were
used for patient selection and collecting background and
follow-up data. CRS diagnosis and operative indications
fulfilled European position paper on rhinosinusitis and nasal
polyps recommendations [15].
The exclusion criteria were: age 513 years; previous or
concomitant additional sinonasal surgery, unilateral CRS or
odontogenic sinusitis, endoscopic signs of nasal polyposis
(grade 2) during the operation, a history of aspirin sensitiv-
ity, chronic bronchitis, cystic fibrosis, primary ciliary dyskin-
esia, tumor, or another disease with a severe impact on general
immunity [16]. Altogether 39 patients in the ESS group and 36
patients in the balloon sinuplasty group met the inclusion
criteria.
Operations
The balloon sinuplasty system was used to dilate the ostium
according to instructions provided by the manufacturer
(Acclarent Inc., a member of Johnson & Johnson Company,
New Brunswick, NJ). To create local anesthesia, three cotton-
tipped applicators soaked in local anesthetic (cocaine hydro-
chloride 120mg + 2.5ml epinephrine 0.1mg/ml) were placed
on each side and 3ml 1% lidocaine adrenalin was infiltrated
around the middle turbinate. Nine out of 25 balloon-patients
that were operated on under local anesthesia also received
additional intravenous sedation, usually midazolam 1–3mg.
During the operation they were given alfentanil total dose
0.5–1.5mg as analgesic. Balloon sinuplasty was performed for
11 (39%) patients in an in-office setting under local anesthesia
without intravenous sedation. No packing was placed and no
post-operative debridement was performed after balloon
dilation.
In the ESS group, partial uncinectomy and middle meatal
antrostomy were performed on both sides. Two thirds of
the lower part of the uncinate process was cut with the
backbiting forceps. The maxillary ostium was enlarged to
posterior–inferior direction to double its diameter. Local
anesthesia was created by placing three cotton-tipped applica-
tors soaked in local anesthetic (75mg cocaine hydrochlor-
ide + 2ml 40mg/ml lidocaine + 0.75ml epinephrine 1mg/ml)
on each side and infiltrating 1.5ml 1% lidocaine adrenalin
around the middle turbinate. A small pack (3.5 0.6 1.2 cm,
Merocel, Medtronic-Xomed, Jacksonville, FL) was placed into
middle meatus for 24 h. Debridement control was 4 weeks
post-operatively. There were no reports of a missed ostium in
the patient records of the ESS or balloon sinuplasty operations.
Phone-interview
A phone interview was conducted in spring 2015. The mean
(min–max) follow-up time was 6.0 (4.9–6.9) years in the ESS
group and 6.4 (5.6–7.3) years in the balloon sinuplasty group.
The phone interview included questions about the patient’s
medical history, e.g. asthma, allergic, aspirin sensitivity,
medication, and smoking habits. Job exposure was evaluated
according to reported current occupation and characterization
of the workplace. The patient was thought to be exposed to
poor indoor air quality if he/she was currently or had been
previously staying longer periods (years) in a place with
discovered mold or water damage. Family history of recurrent
acute/chronic rhinosinusitis or nasal polyposis was deter-
mined. Also the number of sinusitis, lavation of maxillary
sinuses during the past year, and the current use of nasal
corticosteroids were asked about.
Symptom change was evaluated by asking the patient to
compare present symptom level with the situation before the
operation. Patients were instructed to give their answer on a
scale from3 to 3, 0 meaning that the symptom had not
changed,3 meaning that the symptom had become signifi-
cantly worse, and 3 that the patient was now asymptomatic.
Satisfaction was evaluated by the question ‘Would you be
willing to have the same operation now, knowing how much it
would decrease your symptoms?’ Patients who had undergone
revision surgery were advised to give their answer according to
the present status.
No patient reported being unable to answer the interview
because of an inability to remember his/her pre-operative
symptoms.
Statistical analysis
Statistics were performed with SPSS Base 20 Statistical
Software Package (SPSS, Chicago, IL) by AK, ST-S, and
professional statistician H.H. The non-parametric Fisher’s
exact test, Kruskal Wallis, and Mann Whitney U-tests were
used for comparisons of groups. A two-tailed p-value of less
than 0.05 was considered significant in all tests.
Results
Patient characteristics
The ESS and balloon sinuplasty groups were identical in
the duration of CRS symptoms and other patient history
factors (Tables 1 and 2). The pre-operative median radiological
ACTA OTO-LARYNGOLOGICA 533
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 H
els
ink
i] 
at 
00
:38
 09
 M
ay
 20
16
 
Lund-Mackay (LM) score of maxillary sinuses did not differ
between the ESS group and the balloon sinuplasty group
(p40.05, data not shown). On the right side the pre-operative
median LM total score and the median LM score of
ostiomeatal complex were significantly lower in the balloon
sinuplasty group compared to the ESS group (p¼ 0.009 and
p¼ 0.002, respectively). On the left side there were no
significant differences of these LM scores between the ESS
group and balloon sinuplasty group (p40.05). Twenty-five out
of 28 balloon sinuplasty patients and 22 out of 30 ESS patients
were operated upon under local anesthesia. Eleven patients
in the balloon sinuplasty group had the procedure in an
office setting.
Symptom reduction
Both groups experienced equal symptom reduction. The
number of acute sinusitis, thick nasal discharge, and right-
sided nasal blockage were less evidently decreased in the
balloon sinuplasty group (Table 4) No difference was found
between the groups in nasal symptom-score (nasal blockage,
discharge, decreased sense of smell, and facial pain/pressure)
(p40.05).
Results remained similar when patients who had undergone
revision surgery were excluded from the analysis (data not
shown).
Exacerbations
The acute exacerbations were treated according to EPOS, with
inclusion of a Finnish clinical practice of maxillary sinus
lavation or puncture when necessary. The number of maxillary
punctures or lavages during the last year did not differ between
the groups, nor did the number of antibiotic courses for acute
sinusitis (Table 3). Patient-reported number of acute sinusitis
was reduced significantly more in the ESS group (Table 4).
Table 4. Patient-reported change of symptoms an average 6 years after primary
surgery (scale from3 to 3, where3¼ the symptom had become significantly
worse, 0¼ no difference in symptom between pre- and post-operative situation,
3¼ total reduction of symptoms).
Balloon (n¼ 28)
Median (min–max)
ESS (n¼ 30)
Median (min–max) p-value
Decreased sense of smell 0 (–1–3) 0 (–1–3) 0.71
Runny nose 1 (–1–3) 1 (–2–3) 0.51
Post nasal-disharge 0 (–2–3) 1 (–2–3) 0.50
Thick nasal disharge 1 (–1–3) 2 (–2–3) 0.05
Sneezing 0 (–2–3) 0 (–2–2) 0.66
Headache 1 (0–2) 2 (–1–3) 0.85
Cough 0 (–2–3) 1 (–2–3) 0.38
Fever 1 (0–3) 2 (0–3) 0.99
Fatigue 0 (0–3) 0.5 (–1–2) 0.24
Nasal blockage
Right 1 (–2–3) 2 (–1–3) 0.02
Left 2 (–2–3) 2 (–1–3) 0.19
Facial pain/pressure
Right 2 (0–3) 2 (–1–3) 0.53
Left 2 (0–3) 2 (–1–3) 0.53
Ear pain/pressure
Right 0.5 (–2–3) 2 (–1–3) 0.41
Left 0.5 (–2–3) 1 (–1–3) 0.61
Watery eyes
Right 0 (–1–3) 0 (0–2) 0.19
Left 0 (–1–3) 0 (0–2) 0.19
Willingness to have the same operation
Right 3 (–2–3) 3 (–2–3) 0.77
Left 3 (–2–3) 3 (–2–3) 0.94
Number of common colds 0 (0–3) 2 (0–3) 0.16
Duration of common colds 0 (0–3) 0 (0–3) 0.23
Number of acute sinusitis 2 (–2–3) 3 (0–3) 0.01
p-values by Mann-Whitney U-test.
Table 2. Percentage of patients who pre-operatively suffered from listed
symptoms.
Balloon (n¼ 28) ESS (n¼ 30) p-value
Decreased sense of smell 46.4 56.7 0.60
Runny nose 96.4 93.3 1.00
Post nasal-disharge 89.3 93.3 0.67
Thick nasal-disharge 85.7 93.3 0.42
Sneezing 89.3 63.3 0.03
Headache 60.7 60.0 1.00
Cough 78.6 50.0 0.03
Fever 46.4 50.0 0.80
Fatigue 82.1 80.0 1.00
Nasal blockage
Right 96.4 100.0 0.48
Left 96.4 100.0 0.48
Facial pain/pressure
Right 89.3 86.7 1.00
Left 89.3 86.7 1.00
Ear pain/pressure
Right 35.7 50.0 0.30
Left 35.7 50.0 0.30
Watery eyes
Right 53.6 30.0 0.11
Left 53.6 30.0 0.11
p-values by Fisher’s exact test.
Table 1. Patient characteristics.
Patient characteristics
Balloon sinuplasty
(n¼ 28)
ESS
(n¼ 30) p-value
Age, years, mean (min–max) 44 (17–64) 44 (13–75) 0.76
No. of patients with male sex (%) 11 (39) 12 (40) 1.00
Duration of symptoms, mean years
(min–max)
17.4 (0–40) 16.5 (0–55) 0.59
No. of smokers (%) 2 (7) 7 (23) 0.15
No. of patients reporting a doctor-diagnosed (%)
Allergic rhinitis 8 (29) 15 (50) 0.11
Asthma 8 (29) 10 (33) 0.78
No. of patients (%)
With family history of sinusitis/NP 13 (46) 12 (40) 0.51
Using regularly topical nasal steroid 10 (36) 11 (37) 1.00
p-values by Fisher’s exact test (for dichotomous variables) and by Mann-Whitney
U-test (for continuous variables). No., number.
Table 3. Exacerbations and revisions 6 years after primary surgery.
Balloon (n¼ 28) ESS (n¼ 30) p-value
Median (min–max) number of maxillary punctures/lavages during the last year 0 (0–4) 0.5 (0–3) 0.23
Median (min–max) number of antibiotic courses on acute sinusitis during the last year 0 (0–10) 0 (0–3) 0.53
No. of patients with revisions during the follow-up period 4 0 0.05
p-value by Fisher’s exact test (for dichotomous variable) and by Mann-Whitney U-test (for continuous variables).
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Satisfaction
Patients in both groups were equally and well satisfied with the
operation (Table 4). In the ESS group, 22 out of 30 (73%)
patients, and in the balloon group, 18 out of 28 (64%) patients
would definitely be willing to have the same operation.
Revisions
During the follow-up period, from the operation (2008–2010)
until March 2015, four revisions were made in the balloon
sinuplasty group and none in the ESS group (p¼ 0.048 by
Fisher’s exact test, Table 3). Of these four patients, three
underwent ESS: one after 1 year, the second after 2 years, and
the third patient after 4 years from the primary surgery. The
fourth patient had undergone several sinonasal operations
during the follow-up period: ESS of both maxillary sinuses and
anterior ethmoidectomy, one failed attempt of the left frontal
sinus balloon dilation, followed by traditional Draft I proced-
ure of the left frontal sinus. The third patient was operated on
in a private hospital by the same surgeon who did the primary
balloon sinuplasty. The rest of the four revisions were
performed in Tampere University Hospital, by surgeons
other than the one who performed the primary operation.
According to the patient records, revision operation was
performed due to progression of CRS with intra-operative
endoscopic signs of sinus mucosal inflammation and/or
infection. There were no reported signs of failure of the
primary balloon sinuplasty operation, such as missed ostium.
Sub-group analysis
Gender did not affect the results, nor did age or duration of
CRS symptoms. No additional differences were found between
sub-group analysis in patients with allergic rhinitis, asthma, or
nasal polyposis. There was no difference in symptom changes
or satisfaction between patients who had been exposed to bad
indoor air (discovered mold or water damage) or were
smoking. Nasal blockage on both sides (right side: median
¼ 2, min–max¼ 1–3, p¼ 0.001, left side: median¼ 2, min–
max¼ 1–3, p¼ 0.007), and the number of sinusitis (median
¼ 3, min–max¼ 2–3, p¼ 0.012) were reduced significantly
more in the ESS group compared to the balloon group (nasal
blockage right side: median¼ 0, min–max¼ 0–2, left side:
median¼ 0, min–max¼ 0–2; number of sinusitis: median¼ 2,
min–max¼2–3), among patients with occupational risk
factors (textile/wood dust, bad indoor air quality).
Patients reported positive family history of sinusitis or nasal
polyposis did not influence symptom reduction or satisfaction
(p40.05).
Discussion
This study was to compare symptom reduction and satisfac-
tion after maxillary sinus surgery with ESS or balloon
sinuplasty techniques. We demonstrated that both ESS and
balloon sinuplasty seem to retain their efficacy equally,
as measured by reported symptoms and patient satisfaction.
To the knowledge of the authors there exist no previous
controlled studies of balloon sinuplasty with an over 5-years
follow-up. These results are in accordance with our previous
study of symptom improvement with 2-years follow-up, the
subjects of which consisted largely of the same patients [7].
An uncontrolled prospective study performed in-office
balloon sinuplasty on 37 subjects. At 52 weeks, 95% indicated
a willingness to have the procedure again, and 100% (21/21)
would recommend it to family or close friends [17]. This is in
line with our observations of high satisfactions with both ESS
and balloon techniques.
In our study, patients in the balloon sinuplasty group
reported more acute sinusitis during the last year. However, the
number of maxillary punctures/lavages or antibiotic courses for
sinusitis did not differ between the groups. In our 2-year follow-
up study the balloon sinuplasty group reported a higher number
of doctor performed maxillary sinus punctures, ultrasonog-
raphy examinations, and prescribed antibiotic courses for acute
sinusitis during the last 12 months, which differed statistically
significantly from the ESS group [7]. Bikhazi et al. [18] show no
difference in exacerbation rate between balloon and ESS groups
in their 1-year follow-up study.
During the follow-up period of 6 years post-operatively no
revision procedures were performed in the ESS group, whereas
four revisions (14%) were performed in the balloon sinuplasty
group. This finding was statistically significant and could
indicate that maxillary sinus ostium patency might be better
achieved after ESS than balloon sinuplasty. The revisions in the
balloon group were performed by surgeons other than the one
who performed the balloon sinuplasty, which might have
affected the operative decision.
We repeated our analysis after excluding the revision
patients, because we wanted to see if the results had been
biased due to the fact that the revision patients answered
according to their current status. This, however, had no effect
on the results.
The revision rates vary considerably between different
studies due to the heterogeneous study design and follow-up
time. Cutler et al. [13] had a revision rate of 2.0% after
6-months follow-up, and Levine et al. [19] had a rate of 5.8%
after 1-year follow-up. Our revision rate of 14% needs to be
established by other studies with equal follow-up time.
The diversity of the disease restrains the use of balloon as a
single tool in many cases. Further controlled prospective studies
with increased patient numbers are, thus, needed to show which
patients benefit the most from the balloon sinuplasty, so that
the obvious benefits of this tool can be efficiently utilized.
Moreover, it could be possible to speculate that balloon
sinuplasty might establish a position as an in-office treatment
option for CRS patients with plain obstructive disease [20].
We acknowledge that the retrospective nature and relatively
small patient number limit partly the interpretation of the
results. The retrospective study design limited the option to use
a validated quality-of-life test (such as SNOT-22), as the focus
was on the comparison of change in symptoms after the
operation. Yet, the questions used in this study partly
correspond to the questions of SNOT-22. A shortcoming is
that some patients might have had a limited ability to recall
pre-operative symptoms and, thus, to report change in
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symptoms 6 years after the operation. The advantage of the
phone interview was that it was equally performed to both
groups; and it enabled interviewing of the long-distance
patients.
Conclusion
Our study shows that balloon sinuplasty retains its efficacy and
patient satisfaction equally compared to ESS, even after 7 years
from the surgery. Only minor differences were found between
the techniques, with presumably no clinical significance.
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